Literature DB >> 12489489

Involvement of human heparanase in the pathogenesis of diabetic nephropathy.

Avi Katz1, David J Van-Dijk, Helena Aingorn, Arie Erman, Malcolm Davies, David Darmon, Hagit Hurvitz, Israel Vlodavsky.   

Abstract

BACKGROUND: Decreased heparan sulfate proteoglycan content of the glomerular basement membrane has been described in proteinuric patients with diabetic nephropathy. Heparanase is an endo-beta-D-glucuronidase that cleaves negatively charged heparan sulfate side chains in the basement membrane and extracellular matrix.
OBJECTIVES: To investigate whether urine from type I diabetic patients differs in heparanase activity from control subjects and whether resident glomerular cells could be the source of urinary heparanase.
METHODS: Using soluble 35S-HSPG and sulfate-labeled extracellular matrix we assessed heparanase activity in human glomerular epithelial cells, rat mesangial cells, and urine from 73 type I diabetic patients. Heparanase activity resulted in the conversion of a high molecular weight sulfate-labeled HSPG into heparan sulfate degradation fragments as determined by gel filtration analysis.
RESULTS: High heparanase activity was found in lysates of both epithelial and mesangial cells. Immunohistochemical staining localized the heparanase protein to both glomeruli capillaries and tubular epithelium. Heparanase activity was detected in the urine of 16% and 25% of the normoalbuminuric and microalbuminuric diabetic patients, respectively. Urine from 40 healthy individuals did not possess detectable heparanase. Urinary heparanase activity was associated with worse glycemic control.
CONCLUSION: We suggest that heparanase enzyme participates in the tunover of glomerular HSPG. Hyperglycemia enhances heparanase activity and/or secretion in some diabetic patients, resulting in the loss of albumin permselective properties of the GBM.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12489489

Source DB:  PubMed          Journal:  Isr Med Assoc J            Impact factor:   0.892


  17 in total

1.  An ELISA method for the detection and quantification of human heparanase.

Authors:  Itay Shafat; Eyal Zcharia; Benjamin Nisman; Yona Nadir; Farid Nakhoul; Israel Vlodavsky; Neta Ilan
Journal:  Biochem Biophys Res Commun       Date:  2006-01-24       Impact factor: 3.575

2.  Advanced glycation end-products induce heparanase expression in endothelial cells by the receptor for advanced glycation end products and through activation of the FOXO4 transcription factor.

Authors:  Xiao-Fei An; Lei Zhou; Peng-Jun Jiang; Ming Yan; Yu-Jun Huang; Su-Na Zhang; Yun-Fei Niu; Shi-Chao Ten; Jiang-Yi Yu
Journal:  Mol Cell Biochem       Date:  2011-04-02       Impact factor: 3.396

3.  Heparanase regulates thrombosis in vascular injury and stent-induced flow disturbance.

Authors:  Aaron B Baker; William J Gibson; Vijaya B Kolachalama; Mordechai Golomb; Laura Indolfi; Christopher Spruell; Eyal Zcharia; Israel Vlodavsky; Elazer R Edelman
Journal:  J Am Coll Cardiol       Date:  2012-04-24       Impact factor: 24.094

4.  Heparanase levels are elevated in the plasma of pediatric cancer patients and correlate with response to anticancer treatment.

Authors:  Itay Shafat; Ayelet Ben Barak; Sergey Postovsky; Ronit Elhasid; Neta Ilan; Israel Vlodavsky; Miriam Weyl Ben Arush
Journal:  Neoplasia       Date:  2007-11       Impact factor: 5.715

5.  Heparanase induces a differential loss of heparan sulphate domains in overt diabetic nephropathy.

Authors:  T J M Wijnhoven; M J W van den Hoven; H Ding; T H van Kuppevelt; J van der Vlag; J H M Berden; R A Prinz; E J Lewis; M Schwartz; X Xu
Journal:  Diabetologia       Date:  2007-12-06       Impact factor: 10.122

6.  Elevated urine heparanase levels are associated with proteinuria and decreased renal allograft function.

Authors:  Itay Shafat; Amir Agbaria; Mona Boaz; Doron Schwartz; Ronny Baruch; Richard Nakash; Neta Ilan; Israel Vlodavsky; Talia Weinstein
Journal:  PLoS One       Date:  2012-09-13       Impact factor: 3.240

7.  Heparanase levels are elevated in the urine and plasma of type 2 diabetes patients and associate with blood glucose levels.

Authors:  Itay Shafat; Neta Ilan; Samih Zoabi; Israel Vlodavsky; Farid Nakhoul
Journal:  PLoS One       Date:  2011-02-22       Impact factor: 3.240

8.  Heparanase is essential for the development of diabetic nephropathy in mice.

Authors:  Natali Gil; Rachel Goldberg; Tzahi Neuman; Marjolein Garsen; Eyal Zcharia; Ariel M Rubinstein; Toin van Kuppevelt; Amichay Meirovitz; Claudio Pisano; Jin-Ping Li; Johan van der Vlag; Israel Vlodavsky; Michael Elkin
Journal:  Diabetes       Date:  2011-11-21       Impact factor: 9.461

9.  Changes in cultured endothelial cell glycosaminoglycans under hyperglycemic conditions and the effect of insulin and heparin.

Authors:  Juying Han; Fuming Zhang; Jin Xie; Robert J Linhardt; Linda M Hiebert
Journal:  Cardiovasc Diabetol       Date:  2009-08-20       Impact factor: 9.951

10.  High-glucose-induced endothelial cell injury is inhibited by a Peptide derived from human apolipoprotein E.

Authors:  Partha S Bhattacharjee; Tashfin S Huq; Valencia Potter; Anna Young; Ian R Davenport; Richard Graves; Tarun K Mandal; Christian Clement; Harris E McFerrin; Syed Muniruzzaman; Shubha K Ireland; James M Hill
Journal:  PLoS One       Date:  2012-12-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.